JP Morgan Chase
XFOR icon

JP Morgan Chase’s X4 Pharmaceuticals XFOR Stock Holding History

JP Morgan Chase’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
33,552
+33,519
+101,573% +$138K ﹤0.01% 5801
2026
Q1 		$132 Sell
33
-4,548
-99% -$17K ﹤0.01% 7292
2025
Q4 		$18.3K Buy
4,581
+4,548
+13,782% +$16.5K ﹤0.01% 6529
2025
Q3 		$113 Hold
33
– – ﹤0.01% 7160
2025
Q2 		$63 Sell
33
-5,482
-99% -$22.4K ﹤0.01% 6882
2025
Q1 		$39.1K Sell
5,515
-9,807
-64% -$135K ﹤0.01% 5960
2024
Q4 		$337K Buy
15,322
+12,773
+501% +$204K ﹤0.01% 5244
2024
Q3 		$51.2K Buy
2,549
+74
+3% +$1.54K ﹤0.01% 5979
2024
Q2 		$43.1K Buy
2,475
+771
+45% +$25.2K ﹤0.01% 5912
2024
Q1 		$71.1K Sell
1,704
-956
-36% -$26.6K ﹤0.01% 5804
2023
Q4 		$66.9K Hold
2,660
– – ﹤0.01% 5900
2023
Q3 		$87K Sell
2,660
-522
-16% -$22.8K ﹤0.01% 5571
2023
Q2 		$185K Sell
3,182
-17,686
-85% -$909K ﹤0.01% 5115
2023
Q1 		$545K Buy
20,868
+16,881
+423% +$495K ﹤0.01% 4442
2022
Q4 		$119K Buy
+3,987
New +$189K ﹤0.01% 5288
2022
Q1 		– Sell
-7
Closed – – 7079
2021
Q4 		$0 Buy
+7
New +$885 ﹤0.01% 7006
2021
Q3 		– Sell
-1,578
Closed -$308K – 6847
2021
Q2 		$308K Buy
1,578
+44
+3% +$11.1K ﹤0.01% 4999
2021
Q1 		$396K Buy
1,534
+230
+18% +$60.4K ﹤0.01% 4824
2020
Q4 		$252K Buy
1,304
+1,016
+353% +$200K ﹤0.01% 4723
2020
Q3 		$58K Sell
288
-269
-48% -$64.5K ﹤0.01% 4902
2020
Q2 		$155K Buy
557
+430
+339% +$118K ﹤0.01% 4387
2020
Q1 		$38K Sell
127
-3
-2% -$851 ﹤0.01% 4803
2019
Q4 		$42K Hold
130
– – ﹤0.01% 5178
2019
Q3 		$49K Buy
130
+66
+103% +$26.1K ﹤0.01% 5185
2019
Q2 		$30K Buy
64
+57
+814% +$29K ﹤0.01% 5357
2019
Q1 		$4K Sell
7
-3
-30% -$1.66K ﹤0.01% 5635
2018
Q4 		$4K Buy
10
+3
+43% +$1.15K ﹤0.01% 5556
2018
Q3 		$2K Sell
7
-395
-98% -$168K ﹤0.01% 5617
2018
Q2 		$263K Sell
402
-973
-71% -$3.19M ﹤0.01% 4451
2018
Q1 		$5.66M Buy
1,375
+83
+6% +$242K ﹤0.01% 2477
2017
Q4 		$2.97M Buy
+1,292
New +$3.27M ﹤0.01% 3066

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's XFOR Position: Q2 2026 in Review

JP Morgan Chase increased its X4 Pharmaceuticals (XFOR) stake by 101,573% in Q2 2026, buying an estimated $138K and bringing the position to 33,552 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #5801.

JP Morgan Chase first reported a position in XFOR in Q4 2017 and has held it in 31 quarters since. The position peaked at $5.66M in Q1 2018. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • JP Morgan Chase held 33,552 shares of X4 Pharmaceuticals worth $142K as of Q2 2026.
  • JP Morgan Chase bought 33,519 X4 Pharmaceuticals shares in Q2 2026, an estimated $138K.
  • X4 Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5801 holding.
  • JP Morgan Chase first reported a position in X4 Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
  • JP Morgan Chase's X4 Pharmaceuticals position peaked at $5.66M in Q1 2018.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.